Getinge AB beats forecasts with record 2025 growth and rising stock
Getinge AB beats forecasts with record 2025 growth and rising stock
Getinge AB beats forecasts with record 2025 growth and rising stock
Getinge AB has delivered stronger-than-expected results for 2025, beating analyst forecasts with solid revenue growth. The medical technology firm also saw its share price climb sharply on Nasdaq Stockholm after releasing the figures. Industry experts believe the company is well placed to benefit from an ageing population and rising demand for intensive care solutions.
The latest financial report showed robust growth in Getinge's intensive care division, driven by higher sales volumes and price adjustments. Despite ongoing global supply chain pressures, the company kept margins stable through strict cost controls.
Analysts responded positively to the results, with Pareto maintaining a 'buy' rating and setting a target price of 235 SEK. Recent insider purchases further supported confidence in the stock. Several firms also raised their price targets after the strong performance.
Looking ahead, Getinge plans to expand further in 2026, with new product launches in development. The company continues to invest heavily in research and innovation to stay ahead in a competitive market. Its focus on intensive care technology aligns with long-term trends, offering stability compared to more volatile sectors like tech.
Getinge's latest results highlight its ability to grow revenue while managing costs effectively. The company's strategic focus on high-demand medical technology positions it for continued expansion. Investors will now watch for progress on upcoming product releases and further market gains.